Efficacy of centchroman in treating mastalgia and fibroadenoma: A comprehensive institutional analysis

Abstract

Background: Mastalgia and fibroadenoma are common in women under 35. The management of these conditions is not standardized, and most treatments are costly with side effects.

Aims and Objectives: The study aimed to assess the effect of ormeloxifene (Centchroman), a selective estrogen receptor modulator, on mastalgia and fibroadenoma.

Materials and Methods: Women aged 35 and under with benign breast disease sought treatment at a surgery outpatient department from October 2023 to September 2024. They were given a regimen of 30 mg of Centchroman every other day for 12 weeks. Follow-up evaluations occurred at weeks 4, 8, 12, and 24 to track their progress. Results were meticulously assessed through clinical examinations, ultrasound measurements of breast lump size, and pain evaluations using a Visual Analog Scale (VAS). This approach ensures comprehensive care and monitoring for optimal outcomes.

Results: A total of 104 patients were included of which 70 with mastalgia, 34 with fibroadenoma with symptom of pain (non-cyclical in 52 patients and cyclical in 18). Severe pain with VAS score of 10 in 50 patients was noted. Patients with fibroadenoma ranged from 1.5 to 5 cm with either single or multiple in one or both breasts. About 67.14% of patients saw a significant pain reduction from VAS score 10 to 3 in the 1st month. Almost all were painless at 3 months with nodularity disappearance. Mastalgia in fibroadenoma showed mixed response with complete disappearance in 32.35%, partial regression in 47.05%, and no response in 20.59%.

Conclusion: Centchroman is an effective, safe, and inexpensive treatment for mastalgia and fibroadenoma, with minimal side effects such as scanty menses or amenorrhea.